Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexa-Vec vs Sorafenib in Advanced Hepatocellular Carcinoma
CTR20171652Phase 3Suspended
- Sponsor
- SillaJen
- Start
- Jul 2018
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in hepatocellular carcinoma (HCC), sponsored by SillaJen. Started Jul 2018; status: suspended.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20171652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171652.